Group 1 - H&H Group's stock surged over 13%, currently trading at 14.14 HKD with a transaction volume of 91.97 million HKD [1] - The National Bureau of Statistics reported that China's birth population in 2025 is projected to be 7.92 million, indicating increased competition in the infant formula market [1] - According to Lyon, the lower-than-expected birth numbers highlight the importance of product structure and sales momentum for companies, especially as the market shifts towards stage 3 products [1] Group 2 - By 2025, H&H Group's core brand, Biostime, has shown a 10.0% year-on-year growth in infant formula sales in the first half of the year, significantly outperforming the industry average [1] - The strong sales performance of stage 1 and stage 2 infant formula products has been a key driver for the company's growth [1] - Haitong International noted that infant formula has become the largest growth engine for the BNC business [1]
H&H集团午后飙升逾13% 婴幼儿配方粉市场竞争或加剧 合生元为公司核心母婴营养品牌